Evaluating Changes in Systemic Anticancer Therapy Use Between 2015 and 2019
Drug Topics
NOVEMBER 11, 2022
While the use of chemotherapy at end of life is decreasing, the use of immunotherapy is increasing.
STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds
STAT
OCTOBER 25, 2023
The other scenario involved treatments that were more expensive, but no more effective than alternatives, such as the Abraxane chemotherapy. The researchers examined Medicare beneficiaries who were diagnosed with cancer and received treatment from 2014 through 2019.
Chemotherapy 
137
137 Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
‘What a gift to give’: For a woman struggling with infertility, a sister’s unexpected offer of surrogacy brings new hope
STAT
OCTOBER 5, 2022
After the brain tumor diagnosis in 2016, Gatton would undergo two brain surgeries, radiation treatment, chemotherapy, followed by an embryo transfer that failed. But after all that, another embryo transfer had worked, and in fall 2019, Gatton was expecting. Read the rest…
Chemotherapy 101
101 
STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio
STAT
OCTOBER 30, 2023
But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion. STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure.
Chemotherapy 122
122 Chemotherapy 122
122 
STAT+: There’s a bill well-suited for drug shortage reforms, but Congress isn’t interested
STAT
JULY 13, 2023
Although not new, drug shortages are now a crisis, with an increasing number of reports about cancer doctors having to ration chemotherapies and other drugs. At the request of a large bipartisan group of lawmakers, a task force chaired by the Food and Drug Administration in 2019 reported on the root causes of drug shortages.
Chemotherapy 94
94 Chemotherapy 94
94 
Henlius claims win for PD-1 drug in small cell lung cancer
pharmaphorum
DECEMBER 8, 2021
China’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive stage small cell lung cancer (ES-SCLC), setting up regulatory filings.
Chemotherapy 98
98 Chemotherapy 98
98 
Roche extends Kaiku digital monitoring partnership again
pharmaphorum
MAY 10, 2022
The two companies have been working together since 2019 on digital health interventions to provide support to people with cancer, focusing initially on tools for patients undergoing cancer immunotherapy.
Chemotherapy 137
137 
Bid to expand Keytruda use in head and neck cancer therapy fails
pharmaphorum
JULY 21, 2022
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced disease, i.e. recurrent or relapsed HNSCC that has metastasised to other parts of the body.
Chemotherapy 98
98 Chemotherapy 98
98 
Regenxbio expands MPS I gene therapy trial after first look at data
pharmaphorum
FEBRUARY 11, 2022
.” Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I, but that candidate – called SB-318 – flunked out in a clinical trial reported in 2019 and was discontinued.
Chemotherapy 111
111 
Country focus: China & APAC’s growing medical needs bring opportunities and challenges
pharmaphorum
JUNE 8, 2021
Chemotherapy still accounted for 72.6% of the oncology market in China in 2019, compared to 17.1% million in 2019, and are estimated to increase to 5.7 Chemotherapy still plays a significant role in oncology treatment, accounting for 72.6% of the oncology market in China in 2019, compared to 17.1% million in 2030.
Chemotherapy 105
105 
Novartis extends Kaiku digital patient monitoring partnership
pharmaphorum
AUGUST 31, 2022
Kaiku’s DPPM platform has also attracted the attention of other big pharma groups, including Roche which has been working with the company since 2019 on personalised support modules for patients taking its PD-L1 inhibitor Tecentriq (atezolizumab).
Chemotherapy 116
116 
Kite cues up first EMA okay for mantle cell lymphoma CAR-T
pharmaphorum
OCTOBER 19, 2020
MCL is generally treated first with chemotherapy, and patients whose disease progresses despite that can then receive stem cell transplantation or BTK inhibitor drugs like Johnson & Johnson/AbbVie’s Imbruvica (ibrutinib) and AstraZeneca’s Calquence (acalabrutinib).
Chemotherapy 124
124 
Failed trial nixes another FDA approval, this time for BMS’ Istodax
pharmaphorum
AUGUST 4, 2021
The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).
FDA 98
98 
New era of genomic medicine begins as UK approves Lilly’s Retsevmo
pharmaphorum
MARCH 12, 2021
The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional approval for Retsevmo (selpercatinib) as monotherapy for adults with advance RET fusion-positive non-small cell lung cancer requiring systemic therapy after previous immunotherapy and/or chemotherapy treatment.
Chemotherapy 111
111 
Balversa Gets Full FDA Approval for Locally Advanced, Metastatic Urothelial Carcinoma
Pharmaceutical Commerce
JANUARY 19, 2024
Today's approval amends the accelerated approval granted by the FDA in April 2019 to Balversa (erdafitinib) for patients with metastatic urothelial carcinoma with susceptible FGFR2 or FGFR3 alterations following prior treatment with platinum-containing chemotherapy.
FDA 52
52 
AZ claims full control of Caelum’s AL amyloidosis drug in $500m deal
pharmaphorum
SEPTEMBER 29, 2021
Alexion teamed up with Caelum on CAEL-101 in 2019, taking a minority stake in the company, and the partners advanced the drug into the phase 3 CARES programme last year. Each year, an estimated 4,500 people develop AL amyloidosis in the US alone, and there are an estimated 30,000 to 45,000 people living with the disease in the US and Europe.
Chemotherapy 98
98 Chemotherapy 98
98 
BMS sets up Roche, Pfizer rivalry with Turning Point takeover
pharmaphorum
JUNE 6, 2022
Rozlytrek was approved by the FDA in 2019 but has just started to gather sales momentum, making around $17 million in the first quarter of this year, an increase of 78% on the first three months of 2021. Another research note from SVB Securities predicted that repotrectinib could eventually become a $1.5
Chemotherapy 98
98 
FDA starts speedy review of Enhertu in lung cancer
pharmaphorum
APRIL 19, 2022
The review will mainly look at AZ and Daiichi Sankyo’s DESTINY-Lung01, a phase 2 trial which showed a 55% overall response rate for Enhertu in patients previously treated with platinum chemotherapy, mainly partial responses, with a median duration of response of just over 9 months. billion licensing deal for the drug in 2019.
FDA 105
105 
Astellas/Seagen prepare full US filing of bladder cancer drug Padcev
pharmaphorum
FEBRUARY 15, 2021
To recap, Padcev (enfortumab vedotin) was quickly okayed by the FDA in December 2019 in advanced urothelial cancer on the basis of phase 2 response data that made it a rising star at that year’s American Society of Clinical Oncology (ASCO) conference. months in the chemotherapy group. of patients in the chemotherapy arm.
Chemotherapy 69
69 
AstraZeneca to acquire TeneoTwo and its blood-cancer therapeutic
European Pharmaceutical Review
JULY 12, 2022
AstraZeneca’s blood-cancer treatment portfolio already includes Calquence (acalabrutinib), a chemotherapy-free monotherapy for patients with chronic lymphocytic leukaemia (CLL). . The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.
Immunization 98
98 
J&J’s Darzalex Faspro is first US therapy for rare blood disorder
pharmaphorum
JANUARY 18, 2021
Until now people with AL amyloidosis have had to rely on chemotherapy, with its accompanying side effects, and other drugs to tackle organ failure once damage gets severe. Darzalex Faspro looks set to transform the prospects for the 30,000 to 45,000 people in the US and Europe AL amyloidosis patients.
Chemotherapy 98
98 
Intratumoural viral delivery improves glioblastoma survival
European Pharmaceutical Review
MAY 17, 2023
Novel device opens blood-brain barrier to deliver chemotherapy Intratumoural delivery The current trial was designed to evaluate the combination of intratumoural DNX-2401 followed by intravenous pembrolizumab therapy. The study enrolled 49 patients with recurrent GBM from several institutions between September 2016 to January 2019.
Immunization 98
98 
Roche hit by failure of TIGIT drug tiragolumab in lung cancer
pharmaphorum
MARCH 30, 2022
The SKYSCRAPER-02 showed that the combination of the two drugs given on top of chemotherapy was unable to improve progression-free survival versus Tecentriq (atezolizumab) plus chemo in extensive-stage SCLC – a notoriously hard-to-treat form of lung cancer.
Chemotherapy 97
97 
FDA looks at pulling speedy approvals for three cancer drugs
pharmaphorum
APRIL 27, 2021
Today (27 April), the ODAC is due to look at Tecentriq in combination with BMS/Celgene’s Abraxane (nab-paclitaxel) for people with advanced triple-negative breast cancer (TNBC) whose tumours express PD-L1, an indication which was provisionally approved by the FDA in 2019 on the strength of the Impassion130 study.
FDA 90
90 
Sobi gets EU nod for Doptelet in rare blood disorder ITP
pharmaphorum
JANUARY 20, 2021
Sobi acquired Doptelet via its $915 million takeover of Dova Pharmaceuticals in 2019, adding to its haematology and rare disease franchise. The European approval of Doptelet as a second-line treatment for ITP after therapies such as corticosteroids and immunoglobulin drugs comes after a green light by the FDA in July 2019.
Chemotherapy 52
52 
NICE changes stance on Lilly’s breast cancer dug Verzenio
pharmaphorum
AUGUST 11, 2021
. “This is welcome news for my patients, many of whom have already benefitted from the extra time this treatment gives them, without the need for chemotherapy,” said Dr Mark Verrill, a consultant medical oncologist at Newcastle upon Tyne Hospitals NHS Foundation Trust.
Chemotherapy 64
64 
MSD secures full approval for Keytruda’s use in MSI-high solid tumours
Pharmaceutical Technology
MARCH 30, 2023
On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. This announcement is not the only recent development for Keytruda.
Chemotherapy 52
52 
The top 5 pharma M&A deals of 2020
pharmaphorum
DECEMBER 21, 2020
Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.
Chemotherapy 126
126 
Third strike for GSK/Merck as bintrafusp alfa flubs again
pharmaphorum
AUGUST 23, 2021
The latest disappointment has come from the phase 2 INTR@PID BTC 055 study of the drug alongside chemotherapy as a first-line treatment for patients with locally advanced or metastatic biliary tract cancer (BTC), which has been abandoned early. billion deal signed in 2019 that kicked off with a $363 million upfront payment.
Chemotherapy 52
52 Chemotherapy 52
52 
Targeting tumours with novel radiopharmaceuticals
European Pharmaceutical Review
OCTOBER 19, 2023
How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? There is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.
Chemotherapy 105
105 
GSK bails on $4.2bn partnership with Merck on cancer drug
pharmaphorum
OCTOBER 1, 2021
GSK paid $360 million upfront in 2019 for a stake in bintrafusp alfa – a bifunctional fusion protein that targets PD-1 and TGF-beta – but Merck confirmed in a statement that it had no received any milestone payments from the alliance, which had been valued at up to $4.2 billion takeover of Tesaro in 2019.
Chemotherapy 52
52 Chemotherapy 52
52 
Withings adds content to wearables range with 8fit acquisition
pharmaphorum
FEBRUARY 2, 2022
It’s the second acquisition in just a few weeks for Withings , which launched an electrocardiogram (ECG) enabled smartwatch in 2019 in a bid to take on market leader Apple, and also sells ‘smart’ scales and thermometers, blood pressure monitors, and sleep-tracking mattresses.
Chemotherapy 64
64 Chemotherapy 64
64 
GSK’s big-ticket cancer alliance with Merck KGaA stumbles again
pharmaphorum
MARCH 17, 2021
GSK snapped up rights to bintrafusp alfa in 2019, paying around $360 million upfront for a global stake in the drug – a bifunctional fusion protein that targets PD-1 and TGF-beta. The hypothesis that hitting both targets could boost the number of patients responding to PD-1 immunotherapy and the depth of that response is now looking shaky.
Chemotherapy 64
64 Chemotherapy 64
64 
More big wins for the AstraZeneca-Daiichi Sankyo collaboration
Pharmaceutical Technology
AUGUST 16, 2022
In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. months compared with patients treated with standard-of-care chemotherapy.
Chemotherapy 59
59 
Is amoxicillin good for a UTI?
The Checkup by Singlecare
DECEMBER 14, 2023
Sources Community-acquired urinary tract Infection by Escherichia coli in the era of antibiotic resistance , BioMed Research International (2018) Urinary tract infection , Centers for Disease Control and Prevention (2021) Amoxicillin , StatPearls (2022) Uncomplicated urinary tract infections , StatPearls (2023) Beta-lactam antibiotics , StatPearls (..)
Chemotherapy 105
105 
7 Best DRY MOUTH lozenges for saliva production
Druggist
MARCH 11, 2021
Treatment, for example, chemotherapy and radiotherapy. Sci Rep 9, 17648 (2019). Published 2019 Jun 29. One of the most common reasons for dry mouth is dehydration. Other common reasons for dry mouth include: Taking certain drugs (see the next paragraph). Underlying conditions, for example, diabetes or Sjögren’s syndrome.
Packaging 97
97 
Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts say
pharmaphorum
APRIL 28, 2021
The drug was first approved in TNBC in 2019 and there few alternatives for treatment of this aggressive form of the disease. The last few months have seen four occasions in which drugmakers have opted to voluntarily withdraw approvals for cancer drugs that failed confirmatory trials.
FDA 52
52 
J&J bulks up in bispecifics with $1.3bn Xencor alliance
pharmaphorum
OCTOBER 4, 2021
Xencor has previously partnered with MorphoSys and Incyte to test plamotamab in combination with their CD19-targeted antibody Monjuvi (tafasitamab) – plus Bristol-Myers Squibb’s Revlimid (lenalidomide) – as a chemotherapy-free strategy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive type of NHL.
Chemotherapy 52
52 
GSK’s Jemperli/TIM-3 immuno-oncology combo moves to ph3
pharmaphorum
OCTOBER 5, 2022
COSTAR is comparing Jemperli plus cobolimab and docetaxel chemotherapy to Jemperli/docetaxel and docetaxel alone in advanced NSCLC patients whose cancer has progressed after first-line PD-1/PD-L1 inhibitor therapy. billion deal agreed in 2019, along with PARP inhibitor Zejula (niraparib).
Chemotherapy 59
59 Chemotherapy 59
59 
Cost & Management of Oncology Combination Regimens
pharmaphorum
OCTOBER 30, 2019
While combo approaches aren’t new, there are significant cost implications of combining high priced innovator drugs (versus older, generic chemotherapies). Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. Payers are in a difficult spot regarding the cost and management of these regimens.
Chemotherapy 40
40 Chemotherapy 40
40 
EMA starts review of Novartis’ latecomer PD-1 drug tislelizumab
pharmaphorum
APRIL 6, 2022
Novartis said the EMA is assessing the cancer immunotherapy as a first-line treatment alongside chemotherapy for squamous or non-squamous NSCLC and as a second-line monotherapy for this type of cancer, as well as for oesophageal squamous cell carcinoma patients previously treated with chemo.
FDA 52
52 
Gilead moves closer to Chinese filing for Trodelvy in TNBC
pharmaphorum
NOVEMBER 11, 2021
Antibody-drug conjugate Trodelvy (sacituzumab govitecan) is already approved in the US for TNBC, and was licensed for development in China and other Asian territories by Everest in 2019 ahead of Gilead’s $21 billion takeover of its original develop Immunomedics. months in patients treated with chemotherapy. Learn more.
Chemotherapy 52
52 
Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS
pharmaphorum
MAY 11, 2021
That effort is also showing signs of success, with sales of Ultomiris breaking the $1 billion threshold last year, up from $339 million in 2019 but still well behind the $4 billion made by Soliris in 2020.
Chemotherapy 52
52 Chemotherapy 52
52 
CHMP backs Roche’s Enspryng for rare nerve disease NMOSD
pharmaphorum
APRIL 26, 2021
IL-6 inhibitor Enspryng isn’t the first drug to treat NMOSD to get a green light from the CHMP, as Alexion’s complement C5 blocker Soliris (eculizumab) has been approved for the disease in the EU since 2019. However, according to Roche is the only therapy that can be used in adolescents over 12 as well as adults.
Chemotherapy 52
52 Chemotherapy 52
52 
Let's personalize your content